Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Douglas A. McIntyre | Mar 5, 2020 at 12:40 PM EST

Amarin Stock Faces Sell-Off Crisis

Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.

Chris Lange | Mar 5, 2020 at 12:16 PM EST

The Case for 2 Coronavirus Test Companies

More and more companies are joining the fight against the coronavirus. Quest Diagnostics is one of the newest to make…

Paul Ausick | Mar 5, 2020 at 10:05 AM EST

Growing Business Optimism Hampered by Coronavirus Spread

While business leaders remain optimistic about economic prospects this year, the spread of the coronavirus is beginning to tamp down…

Chris Lange | Mar 4, 2020 at 11:35 AM EST

What Arcturus Therapeutics Brings to the Fight Against the Coronavirus

Arcturus Therapeutics stock jumped on Wednesday after the company announced that it would be joining the fight against the latest…

Lee Jackson | Mar 4, 2020 at 9:31 AM EST

Raymond James Makes Huge Changes to Health Care Top Picks List

Ranging from very conservative to aggressive, these Raymond James health care stock picks are good additions to long-term portfolios looking…

Jon C. Ogg | Mar 3, 2020 at 4:05 PM EST

One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment

Peanut allergy is a serious and dangerous, but one biotech may hold the answer that could lead to to a…

Chris Lange | Mar 3, 2020 at 11:25 AM EST

Why Stealth BioTherapeutics FDA Update Is a Big Deal

Stealth Bio stock more than doubled on Tuesday after the company announced a critical update from the FDA.

Jon C. Ogg | Mar 3, 2020 at 10:55 AM EST

Can Co-Diagnostics Dominate Coronavirus News Against New Competition

Co-Diagnostics is a small-cap stock that is far from a household name, but it has received much added exposure of…

Chris Lange | Mar 2, 2020 at 4:21 PM EST

Tilray’s Q4 Up in Smoke

Tilray released fourth-quarter financial results after the closing bell on Monday. The company said that it had a net loss…

Jon C. Ogg | Mar 2, 2020 at 11:35 AM EST

Beam Therapeutics Could See Over 40% Upside Despite Unlucky IPO Timing

The analysts at its underwriting firms are quite positive on Beam Therapeutics, now that its post-IPO quiet period has come…

Chris Lange | Mar 2, 2020 at 9:50 AM EST

Is Gilead Overpaying for Forty Seven?

Forty Seven shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences. But is…

Chris Lange | Feb 28, 2020 at 9:55 AM EST

Are Mylan Results Enough for Investors?

Mylan stock pulled back on Friday after it reported mixed fourth-quarter financial results late Thursday.

Jon C. Ogg | Feb 27, 2020 at 4:30 PM EST

Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development

Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many…

Jon C. Ogg | Feb 27, 2020 at 11:30 AM EST

Teladoc’s Model Supports Strong Growth and Anti-Coronavirus Trading

Teladoc Health is a company that may actually be winning because of the coronavirus outbreak, even if it likely hasn't…

Chris Lange | Feb 27, 2020 at 8:45 AM EST

Big Pharma Scares Off Short Sellers

The February 14 short interest data have been compared with the previous figures, and short interest in most of these…

1 … 67 68 69 70 71 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Amarin Stock Faces Sell-Off Crisis

The Case for 2 Coronavirus Test Companies

Growing Business Optimism Hampered by Coronavirus Spread

What Arcturus Therapeutics Brings to the Fight Against the Coronavirus

Raymond James Makes Huge Changes to Health Care Top Picks List

One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment

Why Stealth BioTherapeutics FDA Update Is a Big Deal

Can Co-Diagnostics Dominate Coronavirus News Against New Competition

Tilray’s Q4 Up in Smoke

Beam Therapeutics Could See Over 40% Upside Despite Unlucky IPO Timing

Is Gilead Overpaying for Forty Seven?

Are Mylan Results Enough for Investors?

Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development

Teladoc’s Model Supports Strong Growth and Anti-Coronavirus Trading

Big Pharma Scares Off Short Sellers

‘Don’t Keep the House If It Steals Your Life’: Dave Ramsey’s Advice to a 41-Year-Old Facing Vision Loss

A $480,000 Portfolio That Showers You With $36,000 a Year Without Touching Principal

Wall Street’s $800 Billion AI Data Center Bet Is Showing Cracks. Only 84 of 157 Gigawatts Will Be Built by 2030

'Don't Keep the House If It Steals Your Life': Dave Ramsey's Advice to a 41-Year-Old Facing Vision Loss

A $480,000 Portfolio That Showers You With $36,000 a Year Without Touching Principal

‘Don’t Keep the House If It Steals Your Life’: Dave Ramsey’s Advice to a 41-Year-Old Facing Vision Loss

A $480,000 Portfolio That Showers You With $36,000 a Year Without Touching Principal

Health and Healthcare Articles

All Health and Healthcare Articles

Amarin Stock Faces Sell-Off Crisis

The Case for 2 Coronavirus Test Companies

Growing Business Optimism Hampered by Coronavirus Spread

What Arcturus Therapeutics Brings to the Fight Against the Coronavirus

Raymond James Makes Huge Changes to Health Care Top Picks List

One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment

Why Stealth BioTherapeutics FDA Update Is a Big Deal

Can Co-Diagnostics Dominate Coronavirus News Against New Competition

Tilray’s Q4 Up in Smoke

Beam Therapeutics Could See Over 40% Upside Despite Unlucky IPO Timing

Is Gilead Overpaying for Forty Seven?

Are Mylan Results Enough for Investors?

Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development

Teladoc’s Model Supports Strong Growth and Anti-Coronavirus Trading

Big Pharma Scares Off Short Sellers

‘Don’t Keep the House If It Steals Your Life’: Dave Ramsey’s Advice to a 41-Year-Old Facing Vision Loss

A $480,000 Portfolio That Showers You With $36,000 a Year Without Touching Principal

Wall Street’s $800 Billion AI Data Center Bet Is Showing Cracks. Only 84 of 157 Gigawatts Will Be Built by 2030

Featured Reads

'Don't Keep the House If It Steals Your Life': Dave Ramsey's Advice to a 41-Year-Old Facing Vision Loss

A $480,000 Portfolio That Showers You With $36,000 a Year Without Touching Principal